Eli Lilly upgrades full-year guidance due to solid growth in Q1

US-based Eli Lilly is upgrading its 2022 revenue outlook in connection with the company’s first quarterly report on Thursday.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app